Stockreport

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights [Yahoo! Finance]

Lexeo Therapeutics, Inc.  (LXEO) 
PDF Reports frataxin protein expression data from a subset of the second dose cohort of SUNRISE-FA, a Phase 1/2 clinical trial of LX2006 for the treatment of Friedreich's a [Read more]